.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
US Department of Justice
Federal Trade Commission
Daiichi Sankyo
Chinese Patent Office
McKesson
Fuji
Merck
Deloitte

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022186

« Back to Dashboard

NDA 022186 describes AK-FLUOR 25%, which is a drug marketed by Akorn and is included in one NDA. It is available from one supplier. Additional details are available on the AK-FLUOR 25% profile page.

The generic ingredient in AK-FLUOR 25% is fluorescein sodium. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fluorescein sodium profile page.

Summary for 022186

Tradename:2
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 022186

Mechanism of ActionDyes

Medical Subject Heading (MeSH) Categories for 022186

Suppliers and Packaging for NDA: 022186

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AK-FLUOR 10% fluorescein sodium INJECTABLE;INTRAVENOUS 022186 NDA Akorn 17478-250 17478-250-20 12 VIAL, SINGLE-DOSE in 1 PACKAGE (17478-250-20) > 2 mL in 1 VIAL, SINGLE-DOSE
AK-FLUOR 10% fluorescein sodium INJECTABLE;INTRAVENOUS 022186 NDA Akorn 17478-253 17478-253-10 12 VIAL, SINGLE-DOSE in 1 PACKAGE (17478-253-10) > 5 mL in 1 VIAL, SINGLE-DOSE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrengthEQ 500MG BASE/5ML (EQ 100MG BASE/ML)
Approval Date:Aug 8, 2008TE:APRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrengthEQ 500MG BASE/2ML (EQ 250MG BASE/ML)
Approval Date:Aug 8, 2008TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Queensland Health
Cipla
Merck
Accenture
Colorcon
Dow
Daiichi Sankyo
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot